Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...

BioCorRx, Inc. Executes Letter of Intent to Sell Rights for the Start Fresh Program in Nevada Los Angeles, May 8, 2014 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX), a leader in addiction treatment and rehabilitation programs, announced it has entered into a letter of intent to sell...

Leading National Pain and Addiction Treatment Specialist Comments on CDC Report HAVRE DE GRACE, MD--(Marketwired - Jul 5, 2013) - The Center for Disease Control and Prevention (CDC) yesterday reported that painkiller overdose deaths among women are up 400 percent over the last...